K
42.26
0.43 (1.03%)
| Previous Close | 41.83 |
| Open | 41.83 |
| Volume | 222,300 |
| Avg. Volume (3M) | 501,298 |
| Market Cap | 3,203,128,576 |
| Price / Earnings (TTM) | 93.91 |
| Price / Sales | 5.52 |
| Price / Book | 6.10 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Mixed | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 0.5 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.10 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
| 52 Weeks Range | ||
| Median | 50.00 (18.32%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 13 Jan 2026 | 50.00 (18.32%) | Buy | 38.60 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LEVY RICHARD S | - | - | 0 | 0 |
| QUART BARRY D | - | 44.38 | -15,960 | -713,574 |
| Aggregate Net Quantity | -15,960 | |||
| Aggregate Net Value ($) | -713,574 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 44.38 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| QUART BARRY D | Director | 04 Feb 2026 | Automatic sell (-) | 2,602 | 43.52 | 113,239 |
| QUART BARRY D | Director | 04 Feb 2026 | Option execute | 2,602 | - | - |
| QUART BARRY D | Director | 03 Feb 2026 | Automatic sell (-) | 12,528 | 44.96 | 563,259 |
| QUART BARRY D | Director | 03 Feb 2026 | Option execute | 12,528 | - | - |
| QUART BARRY D | Director | 02 Feb 2026 | Automatic sell (-) | 830 | 44.67 | 37,076 |
| QUART BARRY D | Director | 02 Feb 2026 | Option execute | 830 | - | - |
| LEVY RICHARD S | Director | 01 Feb 2026 | Option execute | 683 | - | - |
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Kiniksa Pharmaceuticals Provides Corporate Update |
| 07 Jan 2026 | Announcement | Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 12 Nov 2025 | Announcement | Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |